Parkinson’s Muscle Stiffness and Rigidity

Rigidity is one of three cardinal motor symptoms of Parkinson’s disease, and in clinical practice it often turns out to be the most functionally disruptive of the three. Unlike ordinary muscle tightness, it doesn’t ease with rest or gentle movement. It persists, worsens gradually, and over time affects posture, walking, sleep, and the capacity to manage routine physical tasks. 

According to Dr. Guruprasad Hosurkar, a neurologist in Bangalore specialising in Parkinson’s disease and movement disorders, “Rigidity in Parkinson’s is frequently the symptom that causes the most sustained functional impairment, because unlike tremor it doesn’t come and go, it is consistently present and affects everything from walking to sleep quality.”

The source of this stiffness isn’t the muscles themselves, it’s the signalling pathway that controls them, and that distinction changes everything about how rigidity is assessed and treated.

• Dopamine deficit: The substantia nigra degenerates, dopamine falls, and the basal ganglia loses the regulatory capacity that keeps muscle tone in check, leaving muscles locked in contraction without any release signal getting through.
• Disrupted inhibitory signalling: In a healthy system dopamine keeps excitatory and inhibitory muscle commands balanced, remove it and the inhibitory side stops functioning reliably, muscles stay switched on past the point they should release, and on passive examination this registers as cogwheel or lead pipe rigidity.
• Opposing muscles both involved: This is what separates Parkinson’s rigidity from spasticity both agonist and antagonist groups contract at the same time, which is why even simple movements feel mechanically blocked from the inside despite no outward muscle abnormality.
• Starts on one side: In practice, rigidity almost always presents unilaterally first, one arm or one leg, before the other side follows over months or years, generally tracking alongside bradykinesia and postural changes rather than developing independently.

Treatment works, but the right combination depends on how far the disease has progressed and how the rigidity is presenting in that specific patient.

• Start with medication: Levodopa and dopamine agonists work at the source of the problem, restoring enough signalling in the basal ganglia that most patients notice a real reduction in stiffness within the first few weeks of getting the dose right.
• Physiotherapy matters more than patients expect: Sustained contraction slowly narrows joint range of motion if nothing counters it, and structured stretching with resistance training does exactly that, clinical outcomes are consistently better when this starts early, not after stiffness has already set in.
• Botulinum toxin for stubborn focal rigidity: When one particular muscle group isn’t responding to systemic medication, targeted injections reduce local tone in a way tablets simply can’t replicate, with each treatment cycle holding for roughly three to six months.
• DBS for medication-resistant cases: In patients where rigidity is part of broader motor decline that medication is no longer managing, DBS surgery has produced consistent rigidity score improvement, sometimes within days of stimulation parameters being correctly set.

Dr. Guruprasad Hosurkar has 22+ years in neurology and movement disorders, led India’s first Adaptive Closed-Loop DBS programme at KIMS Hospital, and was recognised as Inspiring Neurologist of the Year by the Economic Times in 2021, with patients consistently reporting that motor symptoms were assessed in detail from the first visit and a structured plan was put in place rather than a generalised management protocol.

References:

• Parkinson’s Disease: Mechanisms and Clinical Features — National Institute of Neurological Disorders and Stroke, NIH
• Rigidity and Motor Symptoms in Parkinson’s Disease — PubMed, NCBI